SYN-010 Phase 2 Clinical Trial for IBS-C Conference Call

January 20, 2016 • 8:30am EST

Webcast

Investor Relations

Symbol NYSE MKT: SYN
Price
Change
Volume
Day Low/High
52 Week Low/High

Overview

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In collaboration with Intrexon Corporation (NYSE: XON), the Company is developing preclinical stage monoclonal antibody therapies for the prevention and treatment of Pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).

View Profile

Leadership

Our experienced management team holds an extensive clinical and commercial track record.

Investor Relations

Synthetic Biologics, Inc.
Investor Relations Department
T: (734) 332-7800
info@syntheticbiologics.com

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
#430
Denver, CO 80209
T: (303) 282-4800